Zealand Pharma (CPSE:ZEAL) And The Obesity Story Behind Its Undervalued Narrative
Why Zealand Pharma’s Latest Share Issuance Matters
Zealand Pharma (CPSE:ZEAL) has inched its share capital higher after employees exercised warrants, creating 31,247 new shares that will list on Nasdaq Copenhagen once Danish Business Authority registration is complete.
Recent trading tells a different story to the incremental share issuance. Zealand Pharma’s share price has fallen 15.5% over the past month and is down 39.5% year to date, while the 5 year total shareholder return of 37.7% points to a much stronger long-term journey.
Capitalize on the pressure around Zealand Pharma’s recent share moves by lining it up against our hand picked 185 high quality undervalued stocks that also combine solid cash flows with robust balance sheets.Zealand Pharma’s science story is long term, but the recent share price slide is immediate. So is that gap a chance to pay less for a strong business, or a warning that the current valuation still asks too much?
Most Popular Narrative: 36% Undervalued
Against Zealand Pharma’s last close of DKK278.20, the most followed valuation narrative assigns a fair value of DKK433.36. This creates a sizable gap that hinges on how its obesity pipeline and funding profile evolve.
The growing focus on combination and multi-mechanism obesity drugs (e.g., amylin plus incretin combinations) and accelerated regulatory pathways for innovative peptides aligns with Zealand's core expertise and pipeline, creating opportunities to capture outsized value from industry investment momentum and delivering upside to projected long-term net income as new products reach market.
Curious what kind of revenue reset, margin shift and future earnings multiple are embedded in that DKK433.36 figure. The narrative leans on declining top line, still shrinking earnings and a much higher future P/E to bridge the gap. The mix of falling forecast revenues, high expected losses and a premium earnings multiple is what really drives this valuation story.
Result: Fair Value of DKK433.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, this story can break if key obesity trial readouts disappoint, or if pricing and reimbursement for new therapies tighten more than analysts currently build in.
Find out about the key risks to this Zealand Pharma narrative.
Next Steps
The Zealand Pharma story presents mixed messages, with both risks and rewards in play. This means speed matters, and so does your own homework. Pressure test the bullish and cautious angles by weighing the 1 key reward and 1 important warning sign
Looking for more investment ideas beyond Zealand Pharma?
Do not stop with one ticker. Cast the net wider now so you are not looking back in 12 months wishing you had acted sooner.
- Target potential mispricings by scanning companies that combine quality fundamentals with attractive entry points through the 185 high quality undervalued stocks.
- Strengthen your downside protection by focusing on companies that carry resilient finances using the list of solid balance sheet and fundamentals (195 results).
- Hunt for overlooked opportunities by reviewing a 620 high quality undiscovered gems that most investors are not watching closely yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com